Accelerating and securing the steps that lead from the validation of a new target to the selection of the best antibody candidate

Regularly, new potential therapeutic targets are identified by researchers but only a few of corresponding antibodies will successfully survive the long and costly steps that allow them to be converted into medicine.

By generating antibodies against these new targets and then determining, in vitro and in vivo in relevant models, the existence of a therapeutic window for  a given target/antibody couple, MI-mAbs “de-risk” the process, allowing biopharmaceutical industries to focus their efforts on the safest and most effective antibody candidates.

Devoted to both academic and industrial requirements, Mi-mAbs validates the therapeutic potential of each new target, generates antibodies against the both human and homologous mice target, characterizes their mechanism of action and provides the preclinical data that pave the way for the clinical development of these antibodies. Thus, for each target, Mi-mAbs :

  • Determines its expression profile using immunohistochemistry and bioinformatics

  • Generates antibody candidates (chimeric or humanized, coupled or not with toxins) with isotype adapted to the desired pharmacological profile (cytotoxic antibody, agonists or antagonists)

  • Constructs relevant in vivo models expressing human target (knock-in) upon request

  • Assesses the effectiveness and toxicity of the approach in testing surrogate antibodies (against the homologous murine target) on murine models of grafts of syngeneic tumor cells or testing anti human mAb in knock-in mice (where the murine gene is replaced by a human homologue)

  • Tests the antibody candidates on human cells in vitro and in murine xenograft with cell lines or with patient derived xenografts 

  • Researches biomarkers to facilitate their future clinical development

To do this, the platform is based on 3 key technologies (monoclonal antibodies, immunopharmacology and immunohistochemistry/bioinformatics) and a R&D integrated process that accelerate and secure the steps which lead from the validation of a new target to the selection of the best antibody candidate.